Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AGS 499

Next Previous
Drug Profile

AGS 499

Alternative Names: AGP-499; AGS-499

Latest Information Update: 13 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ben Gurion University
  • Developer Neuromagen Pharma
  • Class Antidementias; Antihyperglycaemics; Cardiovascular therapies; Infertility therapies; Neuroprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Telomerase activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Cardiovascular disorders; Hair disorders; Infertility; Skin disorders; Type 1 diabetes mellitus

Most Recent Events

  • 13 Apr 2026 AGS 499 is still in preclinical development for the treatment of Amyotrophic lateral sclerosis
  • 13 Apr 2026 Neuromagen Pharma has patent protection for "COMPOUNDS FOR THE TREATMENT OF DIABETES AND COMPLICATIONS THAT COME FROM THE SAME DISEASE" in Costa Rica, the US, the European Union, Mexico, Japan, Philippine, South Africa, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, Turkmenistan and Chile and patent pending in China prior to April 2026
  • 13 Apr 2026 Neuromagen Pharma has patent protection for "Telomerase activating compounds for use in fertility and related applications" in Canada prior to April 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top